NCT00634179View on ClinicalTrials.gov

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Lymphoma, B-CellFollicular Lymphoma
Interventions
DRUG

Bortezomib

Bortezomib 1.6 mg/m² given on days 1 and 8

BIOLOGICAL

Rituximab

Rituximab 375 mg/m²

DRUG

Doxorubicin

Doxorubicin 50 mg/m²

DRUG

Cyclophosphamide

Cyclophosphamide 750 mg/m²

DRUG

Vincristine

Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1

DRUG

Prednisone

Prednisone 100 mg/day given orally on days 1-5

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Emory University

OTHER